Towards Healthcare
Cellular Immunotherapy Market Drives by 22.45% CAGR till 2034

Cellular Immunotherapy Market 2025 North America to Lead Growth Amid Rising Cancer Cases and R&D Investments

Projections indicate that, the global cellular immunotherapy market will increase from USD 11.33 billion in 2024 to USD 85.78 billion by 2034, experiencing a CAGR of 22.45% over the next 10 years. The increasing investments in R&D activities, rapid advancements in cell engineering, supportive government framework, and rising prevalence of cancer are expected to drive the growth of the global cellular immunotherapy market over the forecast period.

Content

  • Insight Code: 5968
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The cellular immunotherapy market is projected to reach USD 85.78 billion by 2034, growing at a CAGR of 22.45% from 2024 to 2034.

he cellular immunotherapy market encompasses the development, manufacturing, and commercialization of therapeutic approaches that utilize living cells to stimulate or restore the body immune response against diseases, primarily cancer, but also infectious and autoimmune conditions. This includes T-cell therapies (CAR-T, TCR-T), Natural Killer (NK) cell therapies, Dendritic Cell (DC) therapies, and emerging macrophage-based therapies.

North America is expected to dominate the plastic caps market, followed by Asia Pacific.

The key drivers that mainly boost the market growth include increasing investments in R&D activities, growing demand for personalized medicine, rapid advancements in cell engineering, a supportive government framework, and the rising prevalence of cancer.

The key players include Gilead Sciences, Novartis AG, Bristol Myers Squibb (BMS), Johnson & Johnson + Legend Biotech, Allogene Therapeutics, Adaptimmune Therapeutics, Sana Biotechnology, CRISPR Therapeutics, Fate Therapeutics, Autolus Therapeutics, Precision BioSciences, Poseida Therapeutics, Nkarta, Inc., Celyad Oncology, Caribou Biosciences, Immatics N.V., Tessa Therapeutics, Beigene Ltd., and others.
Any Questions